Summary Levels of circulating soluble intercellular adhesion molecule-1 (sICAM-1) are elevated in patients affected by solid malignancies; however, the cellular sources generating high levels of sICAM-1 remain to be characterized. Using conditioned media (CM) from seven ICAM-1-positive or -negative neoplastic cells, we demonstrate that tumour-derived interleukin 1a (IL-1 a) significantly (P < 0.05) up-regulates the release of sICAM-1 by human umbilical vein endothelial cells. The intensity of the effect correlated with the amounts of IL-la detectable in CM. Levels of ICAM-1 mRNA were also up-regulated by tumour-secreted IL-i a. The up-regulation of the shedding of sICAM-1 and of its expression at protein and mRNA level were completely reversed by the addition of anti-IL-i a neutralizing antibodies. Consistent with the in vitro data, tumour endothelia were strongly stained for ICAM-1 compared with autologous normal tissue endothelia. Taken altogether, our observations reveal an IL-la-mediated tumour-endothelium relationship sustaining the shedding of sICAM-1 by endothelial cells. This is a general phenomenon in solid malignancies that correlates with the ability of neoplastic cells to secrete IL-1a rather than with their expression of ICAM-1 and/or histological origin. sICAM-1 has been previously shown to inhibit LFA-1/ICAM-1-mediated cell-cell interactions; therefore, the ability of neoplastic cells to secrete IL-1a is likely to represent a mechanism for their escape from immune interaction.
1 1O-kDa cell membrane glycoprotein that belongs to the immunoglobulin supergene family (Staunton et al, 1988) . By binding to its counter-receptor, lymphocyte function-associated antigen-I (LFA-1/CD lla), ICAM-1 strengthens cell-cell interactions required for the generation of a variety of immune responses (Maio and Del Vecchio, 1992) . In addition to its expression on immune cells, ICAM-1 is broadly distributed in normal tissues (Smith and Thomas, 1990) , is selectively expressed in human malignancies (Maio et al, 1990; Natali et al, 1990; Vainky et al, 1990 ) and its expression can be regulated by various stimuli on normal (Dustin et al, 1986; Maio et al, 1989; Hashimoto et al, 1994) and neoplastic cells (Schwaeble et al, 1993; Altomonte et al, 1993) .
Constitutive levels of a soluble form of ICAM-I (sICAM-1) have been identified in the serum of healthy subjects (Rothlein et al, 1991; Seth et al, 1991) , and elevated amounts are detectable in inflammatory (Seth et al, 1991; Jones et al, 1995) and autoimmune (Schopf et al, 1993; Sharief et al, 1993) disorders. Furthermore, high levels of sICAM-1 are detectable in malignancies of different histotype and correlate with disease progression (Tsujisaki et al, 1991; Altomonte et al, 1992; Banks et al, 1993; Pui et al, 1993) . This latter finding suggested that elevated levels of sICAM-1 represent an unfavourable prognostic marker in human neoplasias and that sICAM-1 can be used to monitor the clinical course of disease (Altomonte et al, 1992) .
sICAM-1 inhibits non-MHC-restricted (Altomonte et al, 1993) and MHC-restricted (Becker et al, 1993 ) lysis of neoplastic cells by cytotoxic cells and blocks the adhesion of peripheral blood mononuclear cells to malignant cells (Hansen et al, 1994) and to activated endothelia (Hashimoto et al, 1994; Rieckmann et al, 1995) . Thus, sICAM-1 may provide neoplastic cells with different mechanisms of escape from cell-mediated immune surveillance.
ICAM-1-positive neoplastic cells release sICAM-1 (Tsujisaki et al, 1991; Kageshita et al, 1992) , suggesting that they may contribute to the high levels of sICAM-1 detectable in cancer patients. Nevertheless, elevated levels of sICAM-1 are also present in patients affected by ICAM-1-negative malignancies, such as sarcomas (Natali et al, 1990; Pui et al, 1993) , and ovary (Vainky et al, 1990; Banks et al, 1993) and bladder (Banks et al, 1993; Nouri et al, 1996) carcinomas. Moreover, higher levels of sICAM-1 have been found in sera of patients affected by ICAM-1-negative renal cell carcinomas than ICAM-1-positive tumours of similar histotype (Heicappell et al, 1994) . In view of these considerations, it is critical to identify the cellular sources that may contribute to the release of sICAM-1 in ICAM-1-negative malignancies and the mechanism(s) underlying such a phenomenon.
Endothelial cells constitutively express ICAM-1, shed very low levels of sICAM-1 (Hashimoto et al, 1994) and are highly represented within the tumour mass owing to the abundant angiogenesis occurring in solid malignancies (Fox et al, 1996) . Therefore, using conditioned media (CM) from ICAM-1-negative or -positive neoplastic cells, we investigated whether endothelial cells may contribute to the generation of the elevated levels of sICAM-1 detectable in human malignancies and the mechanism(s) underlying the functional relationship between malignant cells and endothelial cells for the shedding of sICAM-1. The melanoma cell line Colo 38 (Altomonte et al, 1993) , the rhabdomyosarcoma cell line A-204, the colon adenocarcinoma cell line DLD-1, the osteosarcoma cell line MG-63, the ovary adenocarcinoma cell line SK-OV-3, the fibrosarcoma cell line HT-1080 and the epithelial bladder carcinoma cell line 5637, purchased from American Type Culture Collection (ATCC, Rockwille, MD, USA), were grown in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS) and 2 mM L-glutamine.
CM were prepared by seeding neoplastic cells and HUVECs in T75 flasks; when cells reached semiconfluence, supernatants were replaced with 10 ml of fresh RPMI-1640 medium and, after 24 h, supematants were collected, centrifuged to remove cell debris, filtered through a 0.22-jim acetate filter, aliquoted and immediately stored at -80°C until use as CM and in ELISA to quantify sICAM-1 and the presence of cytokines. No loss of biological activity was observed over a 3-month period.
MAb and conventional antisera The anti-ICAM-l MAb 84H10, the anti-LFA-3 MAb TS2/9 and the anti-endoglin MAb MAEND3 were developed and characterized as described previously (Sanchez-Madrid et al, 1982; Makgoba et al, 1988; Altomonte et al, 1996) . The anti-HLA class I MAb W6/32 was purchased from ATCC. Dichlorotriazynylaminofluorescein-conjugated F(ab')2 fragments of goat anti-mouse Ig antibodies, Fc fragment specific and ChromePure mouse IgG were purchased from Jackson ImmunoResearch Laboratories, (West Grove PA, USA). IL-la, IL-15, TNF-a and IFN-y neutralizing antibodies were purchased from Genzyme (Cambridge, MA, USA). Culture of HUVECs in the presence of CM HUVECs (5 x 10 ml-') were seeded in 4 ml of culture medium in T25 flasks; the next day the medium was removed and 3 ml of CM was added with or without either a combination of 50 jg ml-' polyclonal rabbit anti-human IL-la and anti-human IL-lI antibodies, neutralizing 50 IU of IL-la and IL-1 P (equivalent to 500 pg), or 10 jl of polyclonal rabbit anti-human TNF-a antibody, neutralizing 1000 IU of TNF-a (equivalent to 100 ng), or 5 jg ml-' of monoclonal mouse anti-human IFN-y antibody, neutralizing 5 x 106 IU of IFN-y (equivalent to 500 jg). After a 24-h incubation, supematants were collected, centrifuged to remove cell debris, filtered through a 0.22-jim acetate filter, aliquoted and immediately stored at -80°C until use in enzymelinked immunosorbent assay (ELISA) to quantify sICAM-1.
British Journal of Cancer (1997) Indirect immunofluorescence was performed as previously described . The double determinant immunoassay to measure sICAM-1 was performed using an ELISA kit from Genzyme. Human IL-a, IL-1,3, TNF-a, TNF-P and IFN-,y were quantitated using ELISA kits purchased from Research and Diagnostic Systems (Minneapolis, MN, USA).
Indirect immunoperoxidase stain was performed using primary MAb at concentration ranging from 10 to 30 gg ml and a commercially available avidine-biotin kit from Vector (Burlingame, CA, USA) as described previous . Figure 1 shows that the mean values ± s.d. of the amounts of detected sICAM-1, subtracted from the amount of sICAM-1 present in CM added to cultures, were 4.7 ± 1.5, 2.5 ± 1, 6.6 ± 0.5, 7 ± 0.9, 6.8 ± 0.4, 8.2 ± 0.6, 11.3 ± 1.9 and 14.9 ± 1.2 ng ml-', for CM from HUVECs, Colo 38, A-204, DLD-1, MG-63, SK-OV-3, HT-1080 and 5637 respectively. In the CM used, the shedding of sICAM-1 by HUVECs was significantly enhanced by CM from HT-1080 (P = 0.004) and 5637 (P = 0.001) cells, compared with CM from HUVECs (Figure 1) . Moreover, the amounts of sICAM-1 released by HUVECs cultured in CM from 5637 cells were significantly (P = 0.02) higher than those of.HUVECs cultured in CM from HT-1080 cells (data not shown).
CM-mediated up-regulation of ICAM-1 expression by HUVECs
As CM from selected neoplastic cells enhanced the release of sICAM-1 by HUVECs, we investigated whether a corresponding increase in the expression of ICAM-1 by HUVECs could be observed. To this end, HUVECs from the experiments described in Figure 1 were assayed for their expression of ICAM-1.
The mean values ± s.d. of mean fluorescence intensity of the constitutive expression of ICAM-1, HLA class I and LFA-3 by HUVECs were 29 ± 12, 120 ± 12 and 21 ± 5 respectively (data not shown). The mean values ± s.d. of mean fluorescence intensity of ICAM-1 expression on HUVECs cultured in CM from HUVECs, Colo 38, A-204, DLD-l, MG-63, SK-OV-3, HT-1080 and 5637 were30±6,32±6,34±3,36±6,75±24, 148±60,212± 17 and 523 ± 130 respectively. ICAM-1 expression was significantly higher on HUVECs grown in CM from MG-63 (P = 0.05), HT-1080 (P = 0.03) and 5637 (P = 0.01) cells, compared with CM from HUVECs (Figure 2) .
The mean values ± s.d. of mean fluorescence intensity of HLA class I expression on HUVECs cultured in CM from HUVECs, Colo 38, A-204, DLD-1, MG-63, SK-OV-3, HT-1080 and 5637 were 132±35, 147±39, 138±50, 155±41, 152±39, 193±64, 181 ± 55 and 247 ± 48 respectively and were significantly higher on HUVECs grown in CM from HT-1080 (P = 0.01) and 5637 (P = 0.005) cells than CM from HUVECs (Figure 2) .
Constitutive levels of cell-surface LFA-3 were not affected by culturing HUVECs in either of the CM used (Figure 2 ).
Detection of cytokines in CM
To characterize tumour-derived factor(s) that may be responsible for the CM-mediated up-regulation of sICAM-1 release by HUVECs, CM were assayed for the presence of IL-la, IL-1p, IFN-y, TNF-a and TNF-,B. IL-la was detectable only in CM from HT-1080 and 5637 cells, with values of 72 pg ml-' and 278 pg ml' respectively; no detectable levels of the other cytokines tested were found (data not shown).
Anti-IL-iac/ antibodies inhibition of CM-induced up-regulation of sICAM-1 release by HUVECs
To determine whether IL-la released by HT-1080 and 5637 cells is responsible for the up-regulation of the shedding of sICAM-1 by HUVECs, cytokine activity neutralization assays were performed.
Results from three independent experiments demonstrated that culturing HUVECs in CM from HT-1080 Analysis of ICAM-1 expression in normal urinary bladder and autologous bladder carcinomas To investigate whether endothelial cells of blood vessels within the tumour mass may express elevated levels of ICAM-1 compared with those in benign tissues, cryostat sections from five Tumour-secreted IL-1o and soluble ICAM-1 1259 D A C Figure 6 Expression of ICAM-1 in normal urinary bladder and autologous malignant tissue as revealed by indirect avidine-biotin immunoperoxidase staining on 4-,um cryostat sections using MAb 84H10. In normal bladder, ICAM-1 specific stain is detected in scattered cells located in the submucosa (A) and occasionally at low level in small vessels of the muscular layers (B). In the autologous tumour tissue, MAb 84H10 decorates interstiiial cells and microvasculature (C) as well as the majority of the vessels of the muscular layers (D). Differences in ICAM-1 vascular expression are also detected in normal submucosa (E) and tumour submucosa (F). Mayer's haematoxylin nuclear counterstain (bar = 23 ,um) normal urinary bladder and autologous bladder carcinomas were stained for ICAM-1 by MAb 84H10. Representative data are shown in Figure 6 , demonstrating that in normal bladder tissues only isolated blood vessels within the chorion tissue and the muscular layer were weakly and heterogeneously stained by MAb 84H10; moreover, scattered cells located in the submucosa stained positive for ICAM-1. In contrast, in the autologous tumour tissue, all detectable blood vessels in the chorion tissue were strongly and homogeneously stained by MAb 84H10, which also stained, to a layer ( Figure 6 ). Epithelial and interstitial cells were also variably stained by MAb 84H10 in selected malignant tissues investigated ( Figure 6 and data not shown).
DISCUSSION
In this study we present the first evidence demonstrating that IL-1 x, secreted at detectable levels by ICAM-1-negative HT-1080 fibrosarcoma cells and 5637 bladder carcinoma cells, significantly lower extent, the majority of blood vessels within the muscular up-regulates the release of sICAM-1 by cultured endothelia. The increase in sICAM-1 release by HUVECs was significantly (P = 0.02, data not shown) higher with CM from 5637 cells than with CM from HT-1080 and was completely abolished by anti-IL-la neutralizing antibodies. In addition, using (Dejana et al, 1988) or tumour-derived (Burrow et al, 1991; Kaji et al, 1995) ILla increases the adhesion of neoplastic cells to HUVECs in vitro and enhances the metastatic potential of neoplastic cells (Giavazzi et al, 1990) , and that IL-1 receptor blockade reduces the number and the size of metastases (Vidal-Vanaclocha et al, 1994) . These tumour spread-promoting effects of IL-la are independent from endothelial ICAM-1 because of the absence of LFA-1 in solid malignancies (Altomonte et al, 1993; Futagami-Mizoguchi et al, 1993) . Nevertheless, IL-la-mediated up-regulation of ICAM-1 expression on endothelia increases immune cells' adhesion and extravasation from blood vessels (Bevilacqua, 1993) and, thus, may contribute to neoplastic cells' destruction by immune effector cells, providing a local inhibition of tumour progression. These counteracting effects of IL-i a on local tumour progression may be explained by our demonstration that tumour-derived IL-la upregulates the constitutive shedding of sICAM-1 by endothelia. In fact, high levels of sICAM-1 generated by tumour-derived IL-laactivated endothelia may decrease immune cells' adhesion to activated endothelia and their subsequent extravasation at tumour sites; moreover, they may also impair LFA-l/ICAM-l-mediated non-MHC-and MHC-restricted cytotoxicity of malignant cells (Altomonte et al, 1993; Becker et al, 1993) .
The evidence that endothelial cells release sICAM-I after being targeted by tumour-derived IL-la is also intriguing in view of the marked angiogenesis occurring in solid tumours (Fox et al, 1996) and of the angiogenic activity of IL-la (Fox et al, 1996) . In fact, tumour-derived IL-1 a may generate sequential events leading to the neoformation of blood vessels and to the consequent up-regulation of sICAM-I release by IL-la-activated tumour endothelia. In this model, IL-la should represent the principal mediator of sICAM-I release by endothelia, and angiogenesis itself should not significantly contribute to the up-regulation of the levels of sICAM-l . In fact, in actively proliferating HUVECs, levels of cell membrane ICAM-I and of sICAM-l do not differ from those of resting HUVECs (E Fonsatti and Maio, unpublished) .
The strong staining for ICAM-1 detected in bladder carcinoma endothelia, compared with endothelia within autologous normal bladder tissues, is consistent with the in vitro data obtained with bladder carcinoma cells 5637 and strongly supports the existence of a tumour-endothelia relationship controlling ICAM-1 expression and shedding by endothelial cells in vivo. This hypothesis is further supported by the lack of modulation of ICAM-I expression and shedding of sICAM-l by HUVECs, that we observed using CM from ICAM-1-positive melanoma cells Colo 38 and by the demonstration that staining for ICAM-1 was similar in blood vessels within skin melanomas as compared with autologous normal skin (Erhard et al, 1996) . Levels of circulating sICAM-1 are elevated in melanoma patients (Altomonte et al, 1992) ; therefore, it can be argued that melanoma cells generate the largest amount of detectable sICAM-1 and that endothelial cells provide a limited support to this event.
Our data, in combination, unveil an IL-la-mediated tumourendothelia relationship that influences the constitutive shedding of sICAM-1 by endothelial cells, that may contribute to the elevation of the levels of sICAM-I in ICAM-l-negative malignancies and that may add to those detectable in ICAM-l-positive malignancies. The identification of IL-la as the tumour-derived soluble mediator that up-regulates the shedding of sICAM-1 by endothelial cells demonstrates that IL-la release by neoplastic cells should be accounted as an additional feature that impairs host-tumour interactions and favours neoplastic cells' escape from immune surveillance.
